NVN Liquidation (DB:6LUA) - Stock Price, News & Analysis

6LUA Stock Overview

NVN Liquidation, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. More details

6LUA fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap (€6K)

Negative shareholders equity

Shares are highly illiquid

Has less than 1 year of cash runway

+ 3 more risks

NVN Liquidation, Inc. Competitors

Real Brands

OTCPK:RLBD

US$2.7k

Bloomios

OTCPK:BLMS

US$6.8k

Avivagen

OTCPK:VIVX.F

US$7.8k

Black Bird Biotech

OTCPK:BBBT

US$3.7k

Price History & Performance

Summary of all time highs, changes and price drops for NVN Liquidation
Historical stock prices
Current Share Price	US$0.001
52 Week High	US$1.97
52 Week Low	US$0.001
Beta	-0.24
11 Month Change	0%
3 Month Change	-97.78%
1 Year Change	-99.92%
33 Year Change	-99.98%
5 Year Change	-99.99%
Change since IPO	-100.00%

Recent updates

Shareholder Returns

	6LUA	DE Pharmaceuticals	DE Market
7D	0%	-1.2%	-0.02%
1Y	-99.9%	-20.1%	8.2%

Return vs Industry: 6LUA underperformed the German Pharmaceuticals industry which returned -26.5% over the past year.

Return vs Market: 6LUA underperformed the German Market which returned 9.5% over the past year.

Price Volatility

Is 6LUA's price volatile compared to industry and market?
6LUA volatility
6LUA Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 6LUA's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine 6LUA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2006	90	n/a	www.novan.com

NVN Liquidation, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete’s foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2.

NVN Liquidation, Inc. Fundamentals Summary

How do NVN Liquidation's earnings and revenue compare to its market cap?
6LUA fundamental statistics
Market cap	€5.14k
Earnings (TTM)	-€29.40m
Revenue (TTM)	€22.86m

0.0x

P/S Ratio

0.0x

P/E Ratio

Is 6LUA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6LUA income statement (TTM)
Revenue	US$24.92m
Cost of Revenue	US$24.45m
Gross Profit	US$473.00k
Other Expenses	US$32.52m
Earnings	-US$32.05m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-1.14
Gross Margin	1.90%
Net Profit Margin	-128.61%
Debt/Equity Ratio	-1,164.1%

How did 6LUA perform over the long term?

See historical performance and comparison

6LUA Stock Overview

Risk Analysis

NVN Liquidation, Inc. Competitors

OTCPK:RLBD

US$2.7k

OTCPK:BLMS

US$6.8k

OTCPK:VIVX.F

US$7.8k

OTCPK:BBBT

US$3.7k

Price History & Performance

Recent News & Updates

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

Nasdaq To Delist the Common Stock of Novan

Novan, Inc.(OTCPK:NOVN.Q) dropped from NASDAQ Composite Index

Novan's Securities to Be Delisted from Nasdaq

Novan Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding MVLS Requirement

Recent updates

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

Nasdaq To Delist the Common Stock of Novan

Novan, Inc.(OTCPK:NOVN.Q) dropped from NASDAQ Composite Index

Novan's Securities to Be Delisted from Nasdaq

Novan Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding MVLS Requirement

First quarter 2023 earnings released: US$0.54 loss per share (vs US$0.71 loss in 1Q 2022)

Novan, Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings released: US$1.42 loss per share (vs US$1.74 loss in FY 2021)

Forecast to breakeven in 2025

Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (Sb206) for the Treatment of Molluscum Contagiosum

Novan, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Novan Announces Publication of Positive Results from Pivotal Phase 3 Study of Berdazimer Gel, 10.3% (Sb206) in Patients with Molluscum Contagiosum in Jama Dermatology

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $14.968192 million.

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $15 million.

Novan, Inc. to Report Q1, 2022 Results on May 16, 2022

Novan, Inc. to Report Fiscal Year 2021 Results on Feb 22, 2022

Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $40.000004 million.

Novan, Inc. Reports Positive Topline Results from Pivotal Phase 3 Trial of Sb206 in Patients with Molluscum Contagiosum

Novan, Inc. Announces Positive Preclinical Data in SB019 COVID-19 Anti-Viral Therapy Program

Novan, Inc. Announces Results from Exploratory Studies Further Demonstrate Antimicrobial Effect of NITRICIL™ Platform Technology with NVN4100 in Companion Animal Health

Novan, Inc. Announces Final Week-12 Visit for Last Patient in B-Simple4 Pivotal Phase 3 Study of Sb206 for Treatment of Molluscum

Novan, Inc. Appoints Steven D. Skolsky to Its Board

Novan, Inc. Contemplates Bankruptcy

Novan Regains Compliance with Nasdaq Minimum Bid Price Requirement

Novan Updates Enrollment for Its B-SIMPLE4 Pivotal Phase 3 Study Evaluating SB206

Novan Exceeds 60% Enrollment in B-Simple4 Pivotal Phase 3 Study of Sb206 for Treatment of Molluscum

Novan Receives Approval from the Listing Qualifications Department of the Nasdaq Stock Market

Novan, Inc. Announces Positive in vitro Results Showing the Potential Efficacy of Its NITRICIL™ Platform Technology as an Antiviral Against SARS-CoV-2 the Virus That Causes COVID-19

Novan, Inc. Announces the Appointment of John M. Gay as Chief Financial Officer

Novan, Inc. May File for Bankruptcy

Earnings released

Novan, Inc.(NasdaqGM:NOVN) dropped from Russell Microcap Value Index

Shareholder Returns

Price Volatility

About the Company

NVN Liquidation, Inc. Fundamentals Summary

0.0x

0.0x

Earnings & Revenue